Critical Insights From Biogen Analyst Ratings: What You Need To Know

During the last three months, 10 analysts shared their evaluations of Biogen BIIB, revealing diverse outlooks from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $308.7, a high estimate of $373.00, and a low estimate of $239.00. A decline of 3.1% from the prior average price target is evident in the current average.

Exploring Analyst Ratings: An In-Depth Overview

A comprehensive examination of how financial experts perceive Biogen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Biogen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biogen's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Biogen analyst ratings.

About Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Financial Milestones: Biogen's Journey

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, Biogen showcased positive performance, achieving a revenue growth rate of 0.87% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Biogen's net margin is impressive, surpassing industry averages. With a net margin of -2.69%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Biogen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.47%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching -0.26%. This signifies efficient management of assets and strong financial health.

Debt Management: Biogen's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.